Exactly. There are several reasonable explanations for Amgen's backing out:
1) Manufacturing issues making it clear that NEO will be very expensive, along with no clear signs of efficacy in early trials. Amgen cuts ties to avoid potential trouble, particularly in light of Aduro backing out on Listeria-based immunotherapy
2) Amgen has decided to refocus their immunotherapy program on antibody-based treatments, and they do not have interest in cell-based programs any more.
"Bad" results aren't coming out yet, no matter what people think. As far as we know, only one patient has been dosed in the NEO study (I don't recall ever getting an update on enrollment). If ADXS-NEO didn't work in that one patient, you have learned basically nothing.
It is reasonable to think that the reason only one patient has been dosed would be for manufacturing concerns, which may or may not be generally associated with neo-antigen approaches in general.
The ultimate fact is that we are not privy to the particulars of this deal, and we do not know why Amgen backed out. Maybe they weren't impressed with Advaxis. Maybe they want to go in a different direction (happens more than you would expect). Maybe there was a disaster (but not one that would require disclosure as a material event).
But it's irresponsible to tell people what the "most likely" explanation really is, particularly one that's not supported by any fact at all.
News 
Market Data 
Discover 
AI
